• Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG; Note=In frame (PubMed=8162068; PubMed=16631476).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (DepMap).
  

PubMed=8162068; DOI=10.1038/ng0294-146
Sorensen P.H.B., Lessnick S.L., Lopez-Terrada D.H., Liu X.F., Triche T.J., Denny C.T.
A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.
Nat. Genet. 6:146-151(1994)

PubMed=16631476; DOI=10.1016/j.cancergencyto.2005.11.006
Szuhai K., IJszenga M., Tanke H.J., Rosenberg C., Hogendoorn P.C.W.
Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines.
Cancer Genet. Cytogenet. 166:173-179(2006)

PubMed=21822310; DOI=10.1038/onc.2011.317
Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V., Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R., Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U., Debiec-Rychter M., Schaefer K.-L., de Alava E.
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Oncogene 31:1287-1298(2012)

PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020
Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P., Schmidt T., Szuhai K., Hogendoorn P.C.W.
CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.
Eur. J. Cancer 51:2624-2633(2015)

PubMed=26979953; DOI=10.1073/pnas.1521251113
Town J., Pais H., Harrison S., Stead L.F., Bataille C., Bunjobpol W., Zhang J., Rabbitts T.H.
Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target.
Proc. Natl. Acad. Sci. U.S.A. 113:3603-3608(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29464090; DOI=10.18632/oncotarget.23815
Spurny C., Kailayangiri S., Altvater B., Jamitzky S., Hartmann W., Wardelmann E., Ranft A., Dirksen U., Amler S., Hardes J., Fluegge M., Meltzer J., Farwick N., Greune L., Rossig C.
T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.
Oncotarget 9:6536-6549(2018)

PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014
Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C., Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J., Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N., Muller I., Walles H., Hartmann W., Rossig C.
EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells.
Mol. Ther. 27:933-946(2019)